06/19/2026
Consider enrollment in this important biomarker study
Have you been diagnosed with schizophrenia spectrum or bipolar spectrum disorders?
Participation in this study is a step to find biological markers for schizophrenia and bipolar spectrum disorders.
The Psychiatric Biomarker Network (formerly the Schizophrenia Spectrum Biomarkers Consortium) was established in November 2018 as a consortium of academic investigators and colleagues from industry with the goal of discovering robust, replicable, and measurable biological markers to support clinical trials for schizophrenia and bipolar spectrum disorders. Click to Learn more. (https://psychiatricbiomarkers.org/)
NAMI Queens/Nassau is providing high level information on namiqn.org and support if you have general questions about this study. Please contact Psychiatric Biomarkers Network and The Feinstein Institutes for Medical Research, Northwell Health with all in depth questions.
Please click here to learn more about this very important work. (https://namiqn.org/resources/consider-enrollment-in-this-important-biomarker-study/)